Medication Management

Introduction to Medication Management

• Medication management involves the use of various medications to treat different medical conditions, with guidelines provided by various societies and authorities, including the American Society of Clinical Oncology, Infectious Diseases Society of America, and American Heart Association 1, 2, 3

Dosage and Administration

• The initial dose of aripiprazole is 5 mg orally daily, with a maintenance dose of 5-15 mg daily based on response and tolerability, as recommended by the American Society of Clinical Oncology 1
• For pain management, methadone should be split into 6-8 hour doses to maintain analgesic effects, according to the Infectious Diseases Society of America 2

Drug Interactions and Monitoring

• The American Society of Clinical Oncology recommends reducing the dose of aripiprazole in patients who are poor metabolizers of cytochrome P450 2D6 1
• The Infectious Diseases Society of America suggests obtaining consultation with a pharmacist when initiating combination therapy to monitor for potential drug interactions affecting metabolism 2
• Patients prescribed methadone through an Opioid Treatment Program should have a signed release for information exchange between prescribers, as recommended by the Infectious Diseases Society of America 2
• Avoid medications that interact with methadone metabolism or increase QTc prolongation risk, and exercise caution with benzodiazepines and other CNS depressants due to risk of respiratory depression, as recommended by clinical guidelines, with a level of evidence B, according to 2

Side Effects and Monitoring

• Common side effects of aripiprazole include headache, agitation, anxiety, insomnia, and dizziness, according to the American Society of Clinical Oncology 1
• Methadone can cause sedation, respiratory depression, and constipation, as reported by the Infectious Diseases Society of America 2
• Methadone therapy is associated with a risk of QTc prolongation and potential for serious arrhythmias, prompting recommendations for initial ECG in all patients starting methadone, especially those with increased risk of arrhythmia, by the American Pain Society, College on Problems of Drug Dependence, and Heart Rhythm Society 2
• The Substance Abuse & Mental Health Services Administration (SAMHSA) recommends baseline ECG recording if the patient has risk factors, with annual ECGs for such patients or when the daily dose exceeds 120 mg, to mitigate the risk of methadone-associated QTc prolongation 3

QTc Prolongation Monitoring and Management

• Baseline EKG should be considered in all patients starting methadone, especially those with a history of cardiac disease, pre-existing QTc prolongation, history of syncope or palpitations, taking other QTc-prolonging medications, electrolyte abnormalities, or planned methadone dose >100 mg/day, as recommended by the American College of Cardiology and supported by 2, 3
• If initial QTc is normal, repeat EKG when reaching 100 mg/day, and consider follow-up EKG at 30 days for patients with risk factors, with a strength of evidence level of moderate, according to 2, 3
• For patients with borderline QTc (450-470 ms), more frequent monitoring (every 2-4 weeks initially) is recommended, and consideration of dose reduction or alternative therapy should be taken, as suggested by the European Heart Rhythm Association and supported by 2
• Methadone dose >100 mg/day is associated with a higher risk of QTc prolongation, with a relative risk of 2.5, as stated by the National Comprehensive Cancer Network and supported by 4, 5
• The following table summarizes the risk levels and recommended actions for QTc intervals:

• If QTc >500 ms, discontinue methadone immediately and switch to an alternative opioid without QTc effects, such as hydromorphone or fentanyl, as recommended by the European Heart Journal and Intensive Care Medicine, with a strength of evidence level of high, according to 6, 3, 7
• If QTc is 450-500 ms, reduce methadone dose by 25-50% and correct electrolyte abnormalities, as suggested by the National Comprehensive Cancer Network and European Heart Journal, with a level of evidence B, according to 4, 3

Alternative Medications and Pain Management

• Buprenorphine causes far less QTc prolongation compared to methadone and may be considered as an alternative, though it is a partial agonist and may be less effective for patients requiring high doses, with a mean difference in QTc prolongation of 20 ms, as suggested by the European Heart Journal and supported by 3
• The most effective non-opioid medications for pain control include gabapentin for neuropathic pain, NSAIDs for inflammatory pain, and tricyclic antidepressants for chronic pain, as recommended by the American College of Physicians, with a level of evidence A, according to 8
• A multimodal approach, combining appropriate medications based on pain type, is recommended, with consideration of topical agents for localized pain, as suggested by the Clinical Infectious Diseases guidelines, with a level of evidence B, according to 2

Monitoring and Follow-up

• Daily ECG monitoring is recommended until QTc normalizes, as suggested by the American Heart Association, with a class I recommendation, as stated by 6
• Continuous cardiac monitoring is recommended in the ICU setting, as stated by Critical Care Medicine, with a level of evidence A, according to 9
• Regular electrolyte monitoring and replacement as needed is recommended, as suggested by the National Comprehensive Cancer Network and American Heart Association, with a level of evidence B, according to 4, 6
• Baseline ECG is particularly important for patients with a history of cardiac disease, pre-existing QTc prolongation, history of syncope or palpitations, or taking other medications known to prolong QTc, to assess the risk of cardiac complications, as recommended by the American College of Cardiology, with a class I recommendation, as stated by 2, 3

Special Considerations

• When switching from methadone to another opioid, fentanyl is preferred in patients with renal failure due to its lack of active metabolites, as recommended by Intensive Care Medicine, with a level of evidence A, according to 7
• Hydromorphone can be used with caution in renal failure, but avoid morphine due to active metabolite accumulation, as warned by Intensive Care Medicine, with a strength of evidence level of moderate, according to 7
• First-line antiemetics that do not prolong QTc include ondansetron, metoclopramide, and dexamethasone, as recommended by the National Comprehensive Cancer Network, with a level of evidence A, according to 4
• Avoid antiemetics known to prolong QTc, such as haloperidol, droperidol, and prochlorperazine, as warned by Critical Care Medicine, with a strength of evidence level of moderate, according to 9